Hannah Mamuszka Net Worth

The estimated Net Worth of Hannah Mamuszka is at least $31.6 Thousand dollars as of 13 June 2023. Ms. Mamuszka owns over 65,789 units of Bionano Genomics Inc stock worth over $31,579 and over the last 4 years she sold BNGO stock worth over $0. In addition, she makes $0 as Director at Bionano Genomics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Mamuszka BNGO stock SEC Form 4 insiders trading

Hannah has made over 1 trades of the Bionano Genomics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently she bought 65,789 units of BNGO stock worth $50,000 on 13 June 2023.

The largest trade she's ever made was buying 65,789 units of Bionano Genomics Inc stock on 13 June 2023 worth over $50,000. On average, Hannah trades about 8,224 units every 0 days since 2020. As of 13 June 2023 she still owns at least 65,789 units of Bionano Genomics Inc stock.

You can see the complete history of Ms. Mamuszka stock trades at the bottom of the page.

Hannah Mamuszka biography

Hannah Mamuszka serves as Director of the Company. Hannah Mamuszka is the founder and Chief Executive Officer of Alva10, an advisory firm focused on creating partnerships between payors and diagnostic companies to increase the value of diagnostic technology, which she founded in March 2016. From December 2010 to June 2015, she served as Vice President of Business Development and Clinical Strategy at Exosome Diagnostics, Inc., a private company developing liquid biopsy tests. Prior to joining Exosome, Ms. Mamuszka served as Director of Strategic Business Development, Companion Diagnostics at Asuragen, Inc., a private company focused on diagnostics and therapeutics. From January 2005 to January 2010, Ms. Mamuszka served in various director level positions, most recently as Global Director for Pharmaceutical Services, at Oncotech Inc., then by acquisition, at Exiqon A/S. Ms. Mamuszka has also served as an Executive Director of Precision Care Alliance, a non-profit focused on policy reform to enable diagnostic development. Ms. Mamuszka has previously held various laboratory positions at ArQule, Inc., Millennium Pharmaceuticals Inc., Organogenesis, Inc. and the National Cancer Institute. Ms. Mamuszka received her BS in neurobiology and physiology from the University of Maryland at College Park and her MS in molecular biology from Harvard University.

What's Hannah Mamuszka's mailing address?

Hannah's mailing address filed with the SEC is C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO, CA, 92121.

Insiders trading at Bionano Genomics Inc

Over the last 6 years, insiders at Bionano Genomics Inc have traded over $0 worth of Bionano Genomics Inc stock and bought 145,814 units worth $129,149 . The most active insiders traders include David L Barker, Christopher P. Stewart, and Christopher J Twomey. On average, Bionano Genomics Inc executives and independent directors trade stock every 75 days with the average trade being worth of $15,253. The most recent stock trade was executed by Hannah Mamuszka on 13 June 2023, trading 65,789 units of BNGO stock currently worth $50,000.

What does Bionano Genomics Inc do?

at bionano genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. our team is not afraid to venture into uncharted territory to look for answers. we welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data. saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. at bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality o

Complete history of Ms. Mamuszka stock trades at Bionano Genomics Inc

Bionano Genomics Inc executives and stock owners

Bionano Genomics Inc executives and other stock owners filed with the SEC include:

• R. Erik Holmlin,
  President, Chief Executive Officer, Director
• Mark Oldakowski,
  Chief Operating Officer
• Dr. Robert Erik Holmlin,
  Pres, CEO, Sec. & Director
• David Barker,
  Independent Chairman of the Board
• Christopher P. Stewart,
  Chief Financial Officer
• Kristiina Vuori,
  Independent Director
• Christopher Twomey,
  Independent Director
• Albert Luderer,
  Independent Director
• Hannah Mamuszka,
  Director
• Yvonne Linney,
  Director
• Alka Chaubey,
  Chief Medical Officer
• Christopher Stewart,
  Chief Financial Officer
• Dr. Charles Lee Ph.D.,
  Scientific Advisor
• Prof. Pui-Yan Kwok,
  Scientific Advisor
• Dr. Paul R. Selvin Ph.D.,
  Scientific Advisor
• Mark Adamchak,
  Controller
• Richard Shippy,
  Chief Bus. Officer
• Robert J. Priar,
  Chief Commercial Officer
• Dr. Alka Chaubey FACMG, Ph.D.,
  Chief Medical Officer
• Aleksandar Rajkovic,
  Director
• Robert J Priar,
  Chief Commercial Officer
• Michael James Ward,
  Former Chief Financial Officer
• Heather Adams,
  Chief Administrative Officer
• Warren Robinson,
  Chief Commercial Officer
• Darren Cai,
  Director
• Quan Zhou,
  Director
• Junfeng Wang,
  Director
• Soheil Shams,
  Chief Informatics Officer
• Richard Shippy,
  Chief Business Officer
• Vincent Jung Fai Wong,
  Director
• Jonathan V. Dixon,
  GENERAL COUNSEL
• Gulsen Kama,
  Chief Financial Officer